Product information and disease descriptionPlace of product in therapyApproaches to treatmentCurrent treatment options and standard of care
Bruton tyrosine kinase inhibitors
12 evidence topics · 8 sources
Remibrutinib: FDA-approved indication, dosage, and surgical interruption
Remibrutinib: mechanism of action
REMIX-1 and REMIX-2: design and Week 12 efficacy in the prescribing information
| Outcome at Week 12 | REMIX-1 remibrutinib (N = 309) | REMIX-1 placebo (N = 153) | REMIX-2 remibrutinib (N = 297) | REMIX-2 placebo (N = 153) |
|---|---|---|---|---|
| LS mean (SE) change in ISS7 | “-9.52 (0.34)” | “-6.89 (0.47)” | “-8.95 (0.34)” | “-5.72 (0.45)” |
| LS mean (SE) change in HSS7 | “-10.47 (0.40)” | “-6.86 (0.55)” | “-10.47 (0.39)” | “-6.00 (0.53)” |
| LS mean (SE) change in UAS7 | “-20.02 (0.72)” | “-13.79 (0.98)” | “-19.41 (0.70)” | “-11.73 (0.95)” |
| UAS7 ≤6, n (%) | “154 (49.8)” | “38 (24.8)” | “139 (46.8)” | “30 (19.6)” |
| UAS7 = 0, n (%) | “96 (31.1)” | “16 (10.5)” | “83 (27.9)” | “10 (6.5)” |
| Treatment difference versus placebo at Week 12 | REMIX-1 | REMIX-2 |
|---|---|---|
| UAS7 difference in LS mean (SE) | “-6.22 (1.14)” | “-7.68 (1.14)” |
| UAS7 95% CI for difference | “-8.45, -4.00” | “-9.91, -5.46” |
| UAS7 ≤6 treatment difference (95% CI) | “25.44”“16.48, 34.39” | “27.61”“19.14, 36.08” |
| UAS7 = 0 treatment difference (95% CI) | “20.55”“13.35, 27.75” | “21.60”“15.10, 28.10” |
REMIX-1 and REMIX-2: Week 12 UAS7 outcomes and adverse events
“A total of 470 patients in REMIX-1 and 455 in REMIX-2 were randomly assigned to receive either remibrutinib (313 and 300 patients, respectively) or placebo (157 and 155 patients, respectively).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The remibrutinib group had a significantly greater decrease in the UAS7 at week 12 than the placebo group (least-squares mean [±SE] change, -20.0±0.7 vs. -13.8±1.0 [P<0.001] in REMIX-1 and -19.4±0.7 vs. -11.7±0.9 [P<0.001] in REMIX-2), which appeared to be sustained through week 24.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 12, significantly more patients in the remibrutinib group than in the placebo group had a UAS7 of 6 or lower (REMIX-1, 49.8% vs. 24.8% [P<0.001]; REMIX-2, 46.8% vs. 19.6% [P<0.001]) and a UAS7 of 0 (REMIX-1, 31.1% vs. 10.5% [P<0.001]; REMIX-2, 27.9% vs. 6.5% [P<0.001]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The percentages of patients with any adverse event and with serious adverse events were similar in the remibrutinib group and the placebo group, although a higher percentage of patients in the remibrutinib group than in the placebo group had petechiae (3.8% vs. 0.3% in the combined groups).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Funded by Novartis Pharmaceuticals;” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
REMIX-1 and REMIX-2: Week 52 efficacy and safety
“Patients were randomized 2:1 to receive oral remibrutinib 25 mg twice daily or placebo during a 24-week double-blind placebo-controlled period, followed by a 28-week open-label treatment period (up to 52 weeks).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“At week 52, patients randomized to remibrutinib showed sustained improvements in change from baseline in weekly Urticaria Activity Score (mean [95% confidence interval], REMIX-1: -23.22 [-24.78, -21.66]; REMIX-2: -22.98 [-24.51, -21.44]), with similar responses observed in patients who transitioned from placebo to remibrutinib at week 24 (observed as early as 1 week after transitioning).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Exposure-adjusted incidence rates of adverse events, serious adverse events, and adverse events leading to discontinuation with 52-week remibrutinib treatment remained equivalent to those in the 24-week analysis.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Pooled REMIX-1 and REMIX-2: disease control, sleep, and quality of life through Week 52
“To evaluate the impact of remibrutinib, an oral, highly selective Bruton's tyrosine kinase inhibitor, on disease control, sleep, and QoL in CSU.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“REMIX-1 (NCT05030311) and REMIX-2 (NCT05032157) were phase 3, double-blind, placebo-controlled studies in adults with CSU who remained symptomatic despite receiving second-generation H1-antihistamines.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“The pooled analysis included 606 and 306 patients receiving remibrutinib and placebo, respectively.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Within 1 week of starting remibrutinib, greater improvements in mean (SD) change from baseline (CFB) compared with placebo were noted in urticaria activity (CFB-Urticaria Activity Score: -11.8 [9.9] and -3.6 [7.6]) and sleep (CFB-Sleep Interference Score: -4.9 [4.9] and -1.9 [4.1]).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Across assessments, responses were sustained through week 52 with remibrutinib, and comparable improvements were observed in those who transitioned to remibrutinib.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remibrutinib: bleeding risk, live vaccines, and adverse reactions in the prescribing information
Pooled REMIX-1 and REMIX-2 safety: bleeding, infections, cytopenia, and hepatic disorders
“This was a pooled analysis of REMIX-1 and REMIX-2 consisting of a 24-week, randomized, double-blind, placebo-controlled period, followed by a 28-week open-label treatment period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“AE frequencies and risk differences (95% CI) for remibrutinib (n = 606) versus placebo (n = 306) were as follows: any AE 64.9% versus 64.7%, difference 0.1% (-6.4% to 6.7%); bleeding (including laboratory abnormalities) 10.6% versus 5.2%, difference 5.3% (1.6% to 8.7%); infections 33.5% versus 34.3%, difference -0.8% (-7.4% to 5.6%); cytopenia AEs 3.6% versus 2.0%, difference 1.7% (-0.7% to 3.8%); hepatic disorders 3.3% versus 4.9%, difference -1.6% (-4.6% to 1.1%).” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Imbalance in bleeding was due to petechia and similar mucocutaneous events (predominantly mild, none severe) occurring in 9.1% of patients on remibrutinib versus 2.0% of patients on placebo.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Findings during the entire study period were consistent with those in the controlled period.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
Remibrutinib: drug interactions and hepatic impairment in the prescribing information
International guideline: remibrutinib suggested as add-on after high-dose H1-antihistamines
“We suggest using remibrutinib” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“as add‐on treatment for patients with CSU unresponsive to high doses of 2nd generation H1‐antihistamines.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The use of remibrutinib can be considered in all patients with CSU and especially in patients who do not respond to both high‐dose antihistamine and omalizumab treatment.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“25 mg twice daily will most likely be recommended as the treatment dose” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rilzabrutinib: RILECSU phase 2 Week 12 results in antihistamine-refractory CSU
“What is the efficacy and risk profile of rilzabrutinib, an oral reversible covalent Bruton tyrosine kinase inhibitor, in adults with antihistamine-refractory chronic spontaneous urticaria (CSU)?” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The Rilzabrutinib Efficacy and Safety in CSU (RILECSU) randomized clinical trial was a 52-week phase 2 study comprising a 12-week, double-blind, placebo-controlled, dose-ranging period, followed by a 40-week open-label extension.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Patients were randomized 1:1:1:1 to rilzabrutinib, 400 mg, once every evening (400 mg/d), twice per day (800 mg/d), 3 times per day (1200 mg/d), or matching placebo.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The primary analysis population included only the 143 omalizumab-naive patients.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Significant reductions at week 12 were observed with rilzabrutinib, 1200 mg/d, vs placebo from baseline in ISS7 (least squares [LS] mean, −9.21 vs −5.77; difference, −3.44 [95% CI, −6.25 to −0.62]; P = .02) and UAS7 (LS mean, −16.89 vs −10.14; difference, −6.75 [95% CI, −12.23 to −1.26]; P = .02).” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Further research is needed to determine long-term efficacy and potential harms.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
Rilzabrutinib adverse events: diarrhea, nausea, and headache
“adverse events occurring at a higher frequency with rilzabrutinib vs placebo included diarrhea, nausea, and headache.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“The most frequent treatment-emergent AEs with rilzabrutinib, 800 mg/d, and rilzabrutinib, 1200 mg/d, were diarrhea and nausea, with most events reported as mild, and none reported as severe.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote